Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited’s share was trading at $31.21 as of April 23rd. TEVA’s trailing and forward P/E were 25.79 and 11.49 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States and internationally. TEVA is advancing a compelling transformation into a branded biopharma innovator, anchored by duvakitug (TEV-48574), a TL1A-targeting monoclonal antibody that is emerging as a potential best-in-class therapy in inflammatory bowel disease (IBD).
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The drug’s differentiated mechanism—blocking pro-inflammatory TL1A-DR3 signaling while preserving the DcR3 decoy pathway—enables a more balanced immune response, which is now translating into superior clinical outcomes.
In Phase 2b maintenance data, duvakitug demonstrated industry-leading efficacy, with 58% clinical remission in ulcerative colitis and 55% endoscopic response in Crohn’s disease at the highest dose, outperforming competing TL1A therapies and comparing favorably even against established biologics. Importantly, these results were achieved with convenient monthly dosing and a clean safety profile, including low immunogenicity rates of 3–5%, reinforcing its suitability as a long-term maintenance therapy.
Beyond efficacy, Teva’s broader strategic repositioning strengthens the investment case. Strong cash flow from branded assets like Austedo is funding late-stage development, while its 50/50 partnership with Sanofi reduces financial risk. Duvakitug itself represents a “pipeline in a molecule,” with expansion opportunities across multiple inflammatory diseases, significantly increasing its total addressable market.
Despite this, the market continues to undervalue Teva, assigning minimal credit to a potential $2.7B–$5.0B peak sales asset. As Teva executes on margin expansion, debt reduction toward ~2x EBITDA, and sustained earnings growth, valuation multiples are poised to re-rate meaningfully, supporting an intrinsic value of $58–60 over the medium term with substantial upside potential.
Previously, we covered a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) by Kontra in April 2025, which highlighted the company’s margin expansion, debt reduction, and growth driven by branded drugs and pipeline catalysts. TEVA’s stock price has appreciated by approximately 123.88% since our coverage. Kontra shares a similar view but emphasizes on duvakitug’s best-in-class clinical data and its potential to drive further valuation upside.
Teva Pharmaceutical Industries Limited is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 60 hedge fund portfolios held TEVA at the end of the fourth quarter which was 60 in the previous quarter. While we acknowledge the risk and potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
